TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05633446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PepGNP-COVID19 (One vaccination)
Description: One dose with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection (One vaccination)
Description: Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PepGNP-COVID19 (Two vaccinations)
Description: Two vaccinations with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection (Two vaccinations)
Description: Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
Study: NCT05714397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal
Description: A single Cingal injection will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
Study: NCT05036460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonography
Description: The transducer will be placed over the anterior neck just above the suprasternal notch, in the transverse orientation. The position of the transducer could be adjusted to visualize both the esophagus and trachea. It will be considered as esophageal intubation if esophageal dilation or double-tract sign are noted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct visualization
Description: While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct visualization
Description: While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.
Study: NCT06024161

Intervention type: OTHER
Intervention: Weight gain
Description: ≥5% weight gain

Intervention type: OTHER
Intervention: Weight loss
Description: ≥5% weight loss after arthroplasty

Intervention type: OTHER
Intervention: Weight unchanged
Description: \<5% weight change after arthroplasty
Study: NCT05911711

Intervention type: OTHER
Intervention: Prognostic factor
Description: normal person (no sepsis group)
Study: NCT06147921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verasone
Description: Administered by sinonasal irrigation.
Study: NCT06052462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3556050
Description: Administered orally
Study: NCT06046690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation Device
Description: During the first week of training, ventilator trigger sensitivity will be initiated at 20% of the patient's baseline MIP (NIF). Patients will train for 5 minutes twice a day for the first days. As the training progresses, the triggering sensitivity will be gradually increased to 30% and 40% of the initial MIP and the duration will be increased up to 30 minutes. During the training sessions, participants will be elevated to a position similar to the Semi-Fowler position at an angle of approximately 45°. Vital signs will be monitored regularly.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Device
Description: The IMT (Inspiratory Muscle Training) with device will commence at 20% of the value obtained from the NIF (Negative Inspiratory Force) measurement or the lowest pressure setting, depending on the patient's tolerance. The duration and intensity will be gradually increased. Once the participants are disconnected from the mechanical ventilator, the IMT device will be connected to the T-tube via a catheter mount with a Catheter Mount. Patients will be instructed to breathe against the resistance set on the IMT device. After completing 8 repetitions, the patient will be allowed to rest for a few minutes. This routine will be repeated for a total of 3 sets of 8 repetitions.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily.
Study: NCT04887311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBM-01
Description: Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
Study: NCT06420908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab+TP/FP+ radiation therapy
Description: Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage:~TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab+FP/TP+ radiation therapy
Description: Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage: (switch to a different chemotherapy drug which not used during the earlier induction phase)~FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs.
Study: NCT06517056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emovi Knee Kinesiography
Description: All participants will receive a KneeKG exam. This device will capture three-dimensional knee kinematics for a participant's knee, using the KneeKG system. Therapists will use these reports and suggested exercises to guide their care for participants in the Intervention group.
Study: NCT06544694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.003% AR-15512
Description: Ophthalmic solution administered via topical ocular instillation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Tears
Description: Commercially available, preservative-free lubricant eye drops
Study: NCT03811405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active biphasic pulse stimulation---Home Settings
Description: During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active biphasic pulse stimulation---VIN Biphasic
Description: During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active biphasic pulse stimulation---Stimulator Off
Description: During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
Study: NCT05564923

Intervention type: DRUG
Intervention: there is no intervention
Description: there is no intervention
Study: NCT05858229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP1
Description: Recombinant Herpes Simplex Virus Type 1 - hGM CSF/GALV-GP-R-
Study: NCT05937100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
Study: NCT05320757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: a PARP inhibitor
Study: NCT05040464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA capsules
Description: oral AZA capsules at a daily dose of 2.5 mg per kilogram,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX 25 mg SC once a week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
Study: NCT05803993

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT) Single FMT infusion
Description: Single FMT infusion via colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) Single FMT infusion
Description: Single FMT infusion via colonoscopy
Study: NCT05881330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArtiAid Intra-articular Injection
Description: Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
Study: NCT03638271

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
Study: NCT05550064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured contraceptive counseling
Description: 1. Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~2. The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~3. A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~4. The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods.
Study: NCT04472208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring solution
Description: Subjects participating in this study will be monitored with the site's standard of care primary monitor and the evaluable device as the secondary monitor.
Study: NCT04847115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative
Description: Intramedullary screw fixation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking boot orthosis
Description: Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking boot orthosis
Description: Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
Study: NCT06511154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: Cognitive rehabilitation is a treatment method used to regain or improve cognitive abilities.For the cognitive rehabilitation program, the Daily Exercise Package of the Norosoft Program, which mainly includes exercises to improve attention, information processing speed, verbal and visual memory functions, will be applied.~Core-based Upper Extremity Exercises~Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core-based Upper Extremity Exercises
Description: Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core-based Upper Extremity Exercises
Description: Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
Study: NCT04820829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High RM, low NSS
Description: Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
Study: NCT06434779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JETi 6F and 8F Thrombectomy system
Description: To demonstrate the efficacy and safety of the mechanical thrombectomy device (JETi 6F and 8F) for treatment of patients with symptomatic peripheral artery disease (PAD) due to acute or acute on chronic occlusions of the femoral and/or popliteal arteries and the first 10 cm of the below-the -knee arteries.
Study: NCT06476821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986435
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986435
Description: Specified dose on specified days
Study: NCT06202079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4 Injection
Description: GZR4 injection s.c., once-weekly, treat-to-target dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin Degludec s.c., once-daily, treat-to-target dose
Study: NCT06404268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor relearning training
Description: Ankle motor control relearning training under real-time feedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive stretching
Description: Passive stretching under intelligent robotic control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamed-based active movement training
Description: Active movement training through movement games with robotic assistance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive movement
Description: Passive movement in the joint middle range of motion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active movement training
Description: Active movement training without robotic assistance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle torque and motion measurement
Description: Ankle torque and motion measurement with no real-time feedback
Study: NCT05094336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: AMG 193: Orally via tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator AMG 193 Test Tablet
Description: Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
Study: NCT06410248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT04820829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate RM, Moderate NSS
Description: Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
Study: NCT05055336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric emptying breath test
Description: The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric emptying breath test
Description: The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stomach ultrasound
Description: Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
Study: NCT06410248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given PO
Study: NCT04820829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low RM, High NSS
Description: Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
Study: NCT05014958

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training on whole body vibration
Description: Participants will be included in the 6-week exercise training on whole body vibration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training on whole body vibration
Description: Participants will be included in the 6-week exercise training on whole body vibration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training on whole body vibration
Description: Participants will be included in the 6-week exercise training on whole body vibration
Study: NCT05413096

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of diclofenac potassium and propolis
Description: Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT06410248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given PO
Study: NCT06275620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-501 (high dose and standard corticosteroid regimen)
Description: Adeno-associated virus vector expressing a human RPGR gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-501 (low dose and standard corticosteroid regimen)
Description: Adeno-associated virus vector expressing a human RPGR gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-501 (high dose and modified corticosteroid regimen)
Description: Adeno-associated virus vector expressing a human RPGR gene